(Q35848356)

10 August 2017

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy (English)

1 reference

10 August 2017

3

Angela Dispenzieri

1 reference

10 August 2017

2

Martha Q Lacy

1 reference

10 August 2017

1

Morie A Gertz

1 reference

10 August 2017

5

Mark R Litzow

1 reference

10 August 2017

4

Philip R Greipp

1 reference

10 August 2017

7

Scott A Van Wier

1 reference

10 August 2017

8

Greg J Ahmann

1 reference

10 August 2017

6

Kimberly J Henderson

1 reference

10 August 2017

Rafael Fonseca

9

1 reference

PMCID

1895302

10 August 2017

language of work or name

English

0 references

publication date

23 June 2005

1 reference

10 August 2017

1 reference

10 August 2017

106

1 reference

10 August 2017

2837-2840

1 reference

10 August 2017

8

1 reference

Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

A molecular study of the t(4;14) in multiple myeloma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895302

t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma

24 September 2018

1 reference

12 December 2020

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

1 reference

12 December 2020

Utility of Interphase FISH Panels for Routine Clinical Cytogenetic Evaluation of Chronic Lymphocytic Leukemia and Multiple Myeloma

1 reference

12 December 2020

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma

1 reference

12 December 2020

Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes

1 reference

12 December 2020

Genomic abnormalities in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants

1 reference

12 December 2020

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

12 December 2020

Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions

1 reference

12 December 2020

10.1182/BLOOD-2005-04-1411

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

PMCID

1895302